+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Detection of human respiratory syncytial virus genotype specific antibody responses in infants



Detection of human respiratory syncytial virus genotype specific antibody responses in infants



Journal of Medical Virology 74(3): 492-498



Infection and reinfection of infants with human respiratory syncytial virus (HRSV) occur despite the presence of serum anti-viral glycoprotein antibodies similar to those, which afford protection in animal models of infection. Antigenic variation of the viral glycoproteins between different genotypes of the virus which co-circulate in the population may contribute to the ability of the virus to escape from antibody-mediated protection. In this study, we have investigated whether human infants infected with HRSV produced antibody responses recognising the antigenic differences between different contemporary genotypes of virus. Acute and convalescent sera from 26 infants were analysed for antibody responses to the glycoproteins of the virus isolated from their respiratory tract and to representative viruses of homologous and heterologous genotypes. All infants developed antibodies with similar reactivity for viruses of all contemporary isolates and genotypes when measured in an immunofluorescence assay against unfixed virus infected cells. However, when antibody responses to the individual glycoproteins were measured in a surace plasmon resonance (SPR) assay, although all infants developed genotype cross-reactive antibodies to the F glycoprotein, anti-G antibodies were detectable in only half of the infants and in all cases these were genotype specific. Possession of no or only genotype specific antibodies to the G glycoprotein may contribute to the susceptibility of infants to reinfection. In both assays, reactivity of anti-glycoprotein antibodies with the sub-group A archetypal strain, A2, was markedly lower than with any contemporary virus tested indicating that this strain alone is unsuitable for accurate assessment of infant antibody responses. .

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011936912

Download citation: RISBibTeXText

PMID: 15368511

DOI: 10.1002/jmv.20203


Related references

Group- and genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia. Journal of Infectious Diseases 207(3): 489-492, 2013

Strain specific antibody responses in infants undergoing primary infection with respiratory syncytial virus. Journal of Infectious Diseases 157(4): 640-647, 1988

Detection of respiratory syncytial virus immunoglobulin g subclass specific antibodies variation according to age in infants and small children and diagnostic value in respiratory syncytial virus infected small infants. Journal of Medical Virology 16(4): 329-336, 1985

Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. Journal of Infectious Diseases 157(4): 640-647, 1988

A prospective comparisons of respiratory syncytial virus rsv subtype specific antibody responses in ribavirin treated and untreated infants and children. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 31: 333, 1991

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 102(3 Part 1): 531-537,., 1998

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatric Infectious Disease Journal 18(3): 223-231, 1999

Role of antibody and the use of respiratory syncytial virus immunoglobulin in the prevention of respiratory syncytial virus disease in preterm infants with and without bronchopulmonary dysplasia. Pediatric Infectious Disease Journal 13(5): 454-7; Discussion 457-8, 1994

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102(3 Pt 1): 531-537, 1998

Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respiratory Medicine 96 Suppl B: S31-S35, 2002

Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections. Journal of Medical Virology 5(2): 161-170, 1980

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. Vaccine 32(37): 4726-4729, 2014

Detection of IgA and IgG but not IgE antibody to respiratory syncytial virus in nasal washes and sera from infants with wheezing. Journal of Pediatrics 138(3): 311-317, 2001

Mucosal respiratory syncytial virus -specific IgA responses in infants following natural RSV infection. Pediatric Research 35(4 Part 2): 185A, 1994